Hosted on MSN24d
Globus Medical Surges 62.1% in a Year: What's Driving the Stock?
Internationally, the power of the combined product offerings is expected to fuel major growth in 2025 and beyond. Innovation remains a key to building long-term growth, with Globus Medical ...
Canaccord maintains Buy rating, $101 target on Globus Medical stock
Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...